(firstQuint)A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv.

 Malignancies.

 This is a multicenter, open-label, safety, tolerability, pharmacokinetic, and activity study.

 Eligible subjects will be adults with advanced solid malignancies.

 Groups of 3 to 6 subjects will receive a single dose of Oradoxel and will be followed for toxicity.

 If non linearity in PK is observed, additional subjects will receive Oradoxel as 2 single daily doses once every three weeks.

 Subjects who tolerate the drug and have stable disease or better response will be eligible to receive ongoing treatment.

.

 A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv.

 Malignancies@highlight

This is a nonrandomized, open-label, dose escalation, safety, activity, and PK study to determine the MTD and optimal dosing regimen of Oradoxel.

 No control group has been included.

